70
Participants
Start Date
June 11, 2020
Primary Completion Date
December 27, 2024
Study Completion Date
October 1, 2025
Phase Ib ARRY-614 + nivolumab
ARRY-614 continuously in 4-week cycles (± 3 days). Nivolumab will be dosed according to FDA-approved dosing schedule.
Phase Ib ARRY-614 + nivolumab+ipilimumab
ARRY-614 continuously in 4-week cycles (± 3 days). Nivolumab will be dosed according to FDA-approved dosing schedule. Ipilimumab therapy will be dosed according to FDA-approved dosing schedule.
Phase II ARRY-614 + nivolumab
"Recommended Phase II dose of ARRY-614 (to be determined) daily in 4-week cycles (± 3 days).~Nivolumab will be dosed according to FDA-approved dosing schedule."
Phase II ARRY-614 + nivolumab+ipilimumab (melanoma)
"Recommended Phase II dose of ARRY-614 (to be determined) daily in 4-week cycles (± 3 days).~Nivolumab will be dosed according to FDA-approved dosing schedule. Ipilimumab therapy will be dosed according to FDA-approved dosing schedule."
Phase II ARRY-614 + nivolumab+ipilimumab (RCC)
"Recommended Phase II dose of ARRY-614 (to be determined) daily in 4-week cycles (± 3 days).~Nivolumab will be dosed according to FDA-approved dosing schedule. Ipilimumab therapy will be dosed according to FDA-approved dosing schedule."
UPMC Hillman Cancer Center, Pittsburgh
Collaborators (1)
Array BioPharma
INDUSTRY
Dan Zandberg
OTHER